Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Shoulder Prosthesis System
2026年6月24日 更新者:TIPMED Medical Device Manufacturing Ltd. Co.
A Multicenter, Prospective, Observational, Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Shoulder Prosthesis System
This study is designed as a prospective, multicenter, observational post-market clinical follow-up (PMCF) study to evaluate the safety and effectiveness of the Tipmed™ Shoulder Prosthesis System at 12 months postoperatively.
The study population includes adult patients who undergo reverse shoulder arthroplasty (RSA) or shoulder hemiarthroplasty (HA) using the Tipmed™ implant systems due to various clinical indications such as osteoarthritis, rotator cuff arthropathy, or proximal humerus fractures.
The main objective is to gather real-world clinical evidence on the 12-month post-operative safety profile, potential complications, and functional outcomes of the device during routine clinical practice.
研究概览
地位
招聘中
详细说明
The European Medical Device Regulation (MDR 2017/745) and corresponding national regulations dictate that additional safety and performance data must be systematically collected for CE-marked medical devices commercialized in the market.
This clinical follow-up trial focuses on patients who are treated within routine medical practice, meaning no intervention or clinical assessment outside of standard scientific guidelines is forced upon the participants.
Data regarding the preoperative status and operative details will be collected retrospectively from patient medical charts.
Postoperative data will be gathered prospectively through regular follow-up visits scheduled at the 6th week, 3rd month, 6th month, and 12th month.
Functional performance will be objectively quantified using the Modified Constant-Murley Score (MCMS).
Quality of life metrics will be assessed via the Short Form-12 (SF-12) questionnaire.
Safety reporting will encompass the continuous tracking and recording of all Adverse Events (AEs), Serious Adverse Events (SAEs), and specific device-related orthopedic complications (e.g., aseptic loosening, infection, dislocation, and scapular notch formation) over the complete 12-month postoperative follow-up period.
Statistical comparisons will be managed separately for the two distinct treatment cohorts: the Reverse Shoulder Arthroplasty cohort and the Hemiarthroplasty cohort.
研究类型
观察性的
注册 (估计的)
54
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Yasemin Önel, Sponsor Rep
- 电话号码:+90 232 479 33 22
- 邮箱:yaseminonel@tipmed.com
学习地点
-
-
-
Balıkesir、土耳其(türkiye)、10100
- 招聘中
- Republic of Turkey Ministry of Health, Balıkesir Provincial Health Directorate, Atatürk City Hospital
-
接触:
- Özgün Karakuş, Assoc. Prof.
- 电话号码:+90 266 460 4000
- 邮箱:ozgunkarakus@hotmail.com
-
首席研究员:
- Özgün Karakuş, Assoc. Prof.
-
副研究员:
- Murat Gök, MD, Spec.
-
Istanbul、土耳其(türkiye)、34303
- 尚未招聘
- Republic of Turkey Ministry of Health, Istanbul Provincial Health Directorate, Kanuni Sultan Suleyman Training and Research Hospital
-
接触:
- Oğuzhan Bulut, MD, Spec.
- 电话号码:+905424096679
- 邮箱:droguzhanbulut@gmail.com
-
首席研究员:
- Oğuzhan Bulut, MD, Spec.
-
Izmir、土耳其(türkiye)、35140
- 尚未招聘
- Republic of Turkey Ministry of Health, Izmir Provincial Health Directorate, Bakircay University Cigli Training and Research Hospital
-
接触:
- Sercan Çapkın, MD, Spec.
- 电话号码:+90506 842 75 96
- 邮箱:sercancapkn@gmail.com
-
首席研究员:
- Sercan Çapkın, MD, Spec.
-
副研究员:
- Murat Kaan Atalay, MD, Spec.
-
Izmir、土耳其(türkiye)、35340
- 尚未招聘
- Dokuz Eylul University Research and Application Hospital
-
接触:
- Onur Başçı, Assoc. Prof.
- 电话号码:+90533 317 99 50
- 邮箱:onur.basci@deu.edu.tr
-
首席研究员:
- Onur Başçı, Assoc. Prof.
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
取样方法
非概率样本
研究人群
The study population comprises adult patients aged 18 years and older, of both sexes, who have undergone either reverse shoulder arthroplasty or shoulder hemiarthroplasty at the participating multi-center orthopedic clinics.
The study population is stratified into two distinct clinical cohorts representing individuals whose surgical treatment involved the standard clinical implantation of the Tipmed™ Shoulder Prosthesis System component options under specific anatomical configurations.
Eligible individuals who are legally competent and provide written informed consent to allow their routine clinical findings to be documented for the study will be consecutively enrolled.
描述
Inclusion Criteria:
- Individuals aged 18 years and older,
- Male or female participants,
- Participants who have undergone Reverse Shoulder Arthroplasty or Shoulder Hemiarthroplasty for any valid indication,
- Participants in whose surgical procedure the Tipmed™ Shoulder Prosthesis System product configurations were utilized.
- Participants who are not legally restricted (e.g., military personnel, convicts, or individuals under legal guardianship).
- Participants who have voluntarily signed the written Informed Consent Form (ICF).
Exclusion Criteria:
- Concurrent participation in any other interventional clinical trial.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Reverse Shoulder Arthroplasty (RSA) Cohort
Patients who undergo reverse shoulder arthroplasty using the Tipmed™ Reverse Shoulder Prosthesis System components (including Humeral Stem, Humeral Tray, Humeral Cup, Glenosphere, Baseplate, and Screws).
Target enrollment: 40 participants.
|
Prospective clinical follow-up and observational data collection for adult patients who have already undergone reverse shoulder arthroplasty using the CE-marked Tipmed™ Reverse Shoulder Prosthesis System in routine clinical practice.
Since participants are enrolled postoperatively, the intervention does not involve any experimental surgical assignment.
No investigational or nonroutine interventions are performed as part of this observational registry.
The tracked device components include a combination of humeral stems available in various dimensional configurations, humeral trays, ultra-high molecular weight polyethylene (UHMWPE) humeral cups, glenospheres, and porous + hydroxyapatite (HA)-coated baseplates with locking or non-locking fixation screws, which were tailored intraoperatively during the index surgery according to the participant's specific shoulder anatomy and bone quality.
|
|
Shoulder Hemiarthroplasty (HA) Cohort
Patients who undergo shoulder hemiarthroplasty involving isolated replacement of the humeral head, using Tipmed™ Humeral Stems and Modular Humeral Heads interacting with the patient's natural glenoid.
Target enrollment: 14 participants
|
Prospective clinical follow-up and observational data collection for adult patients who have already undergone shoulder hemiarthroplasty surgery utilizing specific components of the CE-marked Tipmed™ Shoulder Prosthesis System in routine clinical practice.
Since participants are enrolled postoperatively, this observational study does not involve any active or experimental surgical intervention assigned by the protocol.
No investigational or nonroutine procedures are performed as part of this study.
The tracked intervention evaluates the post-surgical performance of the explicitly isolated replacement of the humeral head interacting with the patient's natural glenoid fossa.
Observational data tracking focuses on the implanted configuration consisting of a modular humeral stem paired with a modular humeral head connected via a tapered conical assembly, which were selected and tailored intraoperatively during the prior surgery based on patient-specific anatomical requirements.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Functional Capacity Assessment via Modified Constant-Murley Score (MCMS)
大体时间:12 months postoperatively
|
The proportion of participants achieving "excellent" (90-100 points) or "good" (80-89 points) functional outcomes based on the total MCMS score.
The MCMS evaluates shoulder function across four domains: pain (15 points), activities of daily living (20 points), active range of motion (40 points), and strength (25 points).
The total score ranges from 0 to 100, where higher scores indicate better functional capacity and superior clinical outcomes.
|
12 months postoperatively
|
|
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:Up to 12 months postoperatively
|
Continuous monitoring, documentation, and cumulative tracking of the incidence of all adverse events (AEs) and serious adverse events (SAEs) occurring throughout the study period, regardless of their causal relationship to the investigational medical device or surgical procedure.
Events will be systematically classified by severity (mild, moderate, severe), outcome, and causality pattern.
|
Up to 12 months postoperatively
|
|
Incidence of Clinical Complications
大体时间:Up to 12 months postoperatively
|
Evaluation of the rate, frequency, and types of all clinical complications recorded throughout the 12-month study period.
This assessment includes intraoperative complications captured retrospectively from surgical medical records (such as humeral or glenoid fractures, vascular injuries, and nerve lesions) as well as longitudinal complications documented prospectively during the postoperative follow-up phase (such as joint dislocation, component loosening, implant breakage, scapular notching, osteolysis, or deep and superficial surgical site infections) associated with the routine clinical utilization of the Tipmed™ Shoulder Prosthesis System.
|
Up to 12 months postoperatively
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Longitudinal Change in Functional Capacity via Modified Constant-Murley Score (MCMS)
大体时间:Retrospective pre-operative baseline, and prospective assessments at 6 weeks, 3, 6, and 12 months post-operatively.
|
Evaluation of the chronological change and improvement in shoulder functional capacity from baseline (preoperative status) across all postoperative follow-up intervals.
Total MCMS scores (0-100 points) will be tracked to capture the transition rates between functional categories: Excellent (90-100), Good (80-89), Fair (70-79), and Poor (<70).
Higher scores reflect progressive functional recovery.
|
Retrospective pre-operative baseline, and prospective assessments at 6 weeks, 3, 6, and 12 months post-operatively.
|
|
Change in Quality of Life via Short Form-12 (SF-12)
大体时间:Retrospective pre-operative baseline, and prospective assessments at 6 weeks, 3, 6, and 12 months post-operatively.
|
Evaluation of the change in health-related quality of life from baseline across all postoperative follow-up points.
The SF-12 is a generic instrument assessing eight dimensions of health status across physical and mental components.
Each subscale is transformed and scored from 0 to 100, where 0 represents the worst health state and 100 represents the optimal health state.
Higher values indicate a superior quality of life.
|
Retrospective pre-operative baseline, and prospective assessments at 6 weeks, 3, 6, and 12 months post-operatively.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 研究主任:Özgün Karakuş, Assoc. Prof.、Republic of Turkey Ministry of Health Balıkesir Provincial Health Directorate, Atatürk City Hospital
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2025年6月16日
初级完成 (估计的)
2030年3月15日
研究完成 (估计的)
2030年6月15日
研究注册日期
首次提交
2026年6月24日
首先提交符合 QC 标准的
2026年6月24日
首次发布 (实际的)
2026年7月1日
研究记录更新
最后更新发布 (实际的)
2026年7月1日
上次提交的符合 QC 标准的更新
2026年6月24日
最后验证
2026年6月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- INFO TPMSP
- 2024-199 (其他标识符:Turkish Medicines and Medical Devices Agency (TITCK))
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
IPD 计划说明
Individual Participant Data (IPD) will not be shared publicly due to the strict confidentiality requirements, personal data protection legislation (KVKK Law No.6698), and commercial intellectual property rights policies of the sponsor.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.